Skip to content
Toggle Navigation
COA INITIATIVES
COA Administrators’ Network (CAN)
Community Oncology Pharmacy Association (COPA)
COA Patient Advocacy Network (CPAN)
COA Fellows Initiative
Enhancing Oncology Model Support Network (EOM)
National Cancer Treatment Alliance (NCTA)
Oncology Medical Home (OMH)
EVENTS
Community Oncology Conference
Payer Exchange Summit
State of Community Oncology Briefing
Advocacy Chats
Advocacy Summit
Partner Events
Webinars
All COA Events
GET INVOLVED
Membership Benefits
Join Now
Search for:
MyCOA
Toggle Navigation
Education & Publications
Studies
Comment Letters
Practice Impact Reports
PBM Horror Stories
Position Statements
All Publications
Practice Resources
COA Initiatives
COA Quality & Value Standards
Policy Tracker & Maps
Patient Feedback Tools
Practice Benchmarking Software (COAnalyzer)
Addressing PBM & Insurer Abuses
COA TV
Advocacy
Take Action Center
Patient Advocacy & Education (CPAN)
Sit in My Chair Elected Official Visits
State Legislative Leadership
Comment Letters
Position Statements
News & Updates
Press Releases
Latest Updates
Industry News
Newsletters
About
Who We Are
What is Community Oncology?
Our Members & Community
Board & Leadership
Committees & Boards
Contact Us
Amgen, Lilly Are Part of Ongoing Senate Probe Into Pharma’s Restrictions on 340B Program
Published On: September 25th, 2024
Categories:
Latest News
Amgen, Lilly Are Part of Ongoing Senate Probe Into Pharma’s Restrictions on 340B Program
Published On: September 25th, 2024
Categories:
Latest News
Page load link
